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Abstract
Hypoxic-ischemic (HI) insult in the perinatal phase harbors a high risk of encephalopathy in the neonate. Brain cells undergo
apoptosis, initiating neurodegeneration. So far, therapeutic approaches such as cooling remain limited. Transplantation of
mesenchymal stem cells (MSCs) exhibits therapeutic success despite the short-time survival in the host brain, providing strong
evidence that their beneficial effects are largely based on secreted factors, including extracellular vesicles (EVs). The aim of this
study was to investigate the effects of human Wharton’s jelly MSC (hWJ-MSC)-derived EVs on neuroprotection and neu-
roregeneration, using an in vitro model of oxygen–glucose deprivation/reoxygenation (OGD/R) mimicking HI injury in the
mouse neuroblastoma cell line neuro2a (N2a). hWJ-MSC-derived EVs were isolated from cell culture supernatants by mul-
tistep centrifugation and identified by endosomal marker expression and electron microscopy. OGD/R significantly increased
DNA fragmentation and caspase 3 (Casp3) transcription in N2a cells relative to undamaged cells. OGD/R-mediated DNA
fragmentation and Casp3 expression could be prevented as well as resolved by the addition of hWJ-MSC-derived EV before
and after OGD, respectively. hWJ-MSC-derived EV also tended to increase the phosphorylation of the B cell lymphoma 2
(Bcl2) family member Bcl-2-antagonist of cell death (BAD) in N2a cells, when added prior or post OGD, thereby inactivating
the proapoptotic function of BAD. Fluorescence confocal microscopy revealed the close localization of hWJ-MSC-derived EVs
to the nuclei of N2a cells. Furthermore, EVs released their RNA content into the cells. The expression levels of the
microRNAs (miRs) let-7a and let-7e, known regulators of Casp3, were inversely correlated to Casp3. Our data suggest that
hWJ-MSC-derived EVs have the potential to prevent and resolve HI-induced apoptosis in neuronal cells in the immature
neonatal brain. Their antiapoptotic effect seems to be mediated by the transfer of EV-derived let-7-5p miR.
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Introduction
The human brain has a great demand for oxygen and glu-
cose, which are used in oxidative phosphorylation to gener-
ate adenosine triphosphate (ATP), providing chemical
energy to the cell. Hypoxia-ischemia (HI) leads to the rapid
reduction in oxidative phosphorylation and, subsequently, to
primary energy failure in glutamatergic neuronal cells1. HI
in the perinatal phase reduces the ATP availability and fre-
quently leads to brain injury implying inflammation and cell
death. In contrast to the adult brain, the prominent kind of
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cell death in the neonatal brain after HI is the highly regu-
lated programmed cell death, namely, apoptosis2,3. Caspase-
dependent death pathways are activated in many brain cell
types, initiating neurodegeneration4–6. Severe lifelong
neurodevelopmental manifestations, such as motor deficits
including cerebral palsy, can be a consequence. Together
with the severity of the HI insult, the maturity degree of the
brain determines the severity of HI brain damage, thus,
increasing the risk of encephalopathy in preterm neonates7.
To date, hypothermia is the only therapeutic intervention
used clinically for infants with HI brain damage born at term
or late preterm (35 wk of gestation). Although it lowers
infant mortality and morbidity, therapeutic hypothermia
does not guarantee complete protection8,9. Because of the
lack of an effective therapy for premature infants,
supportive care is the only available treatment option after
preterm HI brain damage. Hence, there is an immediate need
for selective therapeutic agents.
We and others have shown that the transplantation of
mesenchymal stem cells (MSCs) has neuroregenerative
potential in animal models of perinatal HI brain injury.10–
12 As transplanted MSCs have beneficial effects in spite of
low long-ranging survival in host tissue13, the therapeutic
impact of applied MSCs largely relies on released factors,
including extracellular vesicles (EVs)14,15. When EVs were
discovered over 30 y ago16,17, they were considered a by-
product of the cells without specific functions. However,
since Raposo et al. revealed the intercellular communication
potential of EVs in 199618, and the significance of the inter-
cellular transport of proteins, lipids, and nucleic acids by
EVs has been emphasized by numerous publications19. EVs
can be classified into apoptotic bodies, microvesicles (MVs),
and exosomes. MVs and exosomes both contain nucleic
acids, lipids, and cytoplasmic and membrane proteins. How-
ever, they differ in size and biogenesis. While MVs have a
diameter of 50 to 1,000 nm and are shed directly from the
plasma membrane, exosomes have a diameter of 30 to
120 nm and originate from the endosomal membrane20. The
exact differences between MVs and exosomes has been
shown to be complex and led to confusion among scientists.
Thus, we will use EVs as an umbrella term, as recommended
by the International Society of Extracellular Vesicles. In
2011, Zhuang et al. successfully transplanted EVs intrana-
sally in mouse models of brain inflammatory diseases21. EVs
reached the brain within 30 min21. Furthermore, MSC-
derived EVs have been shown to exhibit neuroregenerative
potential in rodent stroke models by inducing neurite out-
growth22, reducing motor coordination deficits, and increas-
ing angioneurogenesis23,24. In an ovine model of preterm HI
brain injury, Ophelders et al. recently demonstrated that the in
utero intravenous administration of bone marrow–derived
MSC (BM-MSC)-EVs after global HI decreased the number
and duration of seizures and tended to obviate hypomyelina-
tion25. These observations make EVs a promising alternative
to MSCs to treat perinatal HI brain injury. Furthermore, ther-
apeutic intervention with EVs provides huge advantages over
cell-based therapy26–28. EVs are not viable, making them safer
for storage at 20 C without the addition of cryoprotectant
solutions. They are less immunogenic than the mother cell,
and the applied dose and biological activity can bemore easily
standardized. Furthermore, EVs are stable in bodily fluids and
their contents are naturally protected from degradation, mak-
ing them more advantageous over soluble molecules. For
example, free RNA is rapidly degraded.
To date, the molecular mechanisms of the therapeutic
effects of EVs are not fully understood. EVs contain a lot of
bioactive molecules, which could be transferred to target
cells. In addition to proteins, lipids, DNA, and mRNA,
small noncoding microRNA (miR) play a key role in gene
regulation and have been detected in EVs29. Thus, most
studies analyzing MSC-derived EVs showed that miR ori-
ginating from EVs influenced the fate of target cells. In
2012, Xin et al. documented that the increased neurite out-
growth of neural cells in a rat model of middle cerebral
artery occlusion (MCAO) after transplantation of BM-
MSCs relied on the transfer of miR-133b by BM-MSC-
derived EVs into host neural cells22. Furthermore, in a rat
model of primary brain tumor, the injection of EVs derived
from miR-146 expressing MSCs into gliomas significantly
reduced glioma growth30. The observation that MSC-
derived EVs are able to reprogram tumor cells by the trans-
fer of miR has become substantiated by Lee and cowor-
kers31. They showed that EV-derived miR-16, which is
known to target VEGF, was in part accountable for the
antiangiogenic effect in breast cancer cells.
Thus, in the present study, we evaluate the neuroprotec-
tive and neuroregenerative effects of human Wharton’s jelly
MSC (hWJ-MSC)-derived EVs on neuroblastoma cells in an
in vitro model of HI damage.
Materials and Methods
Isolation and Culture of Human Wharton’s Jelly-
derived Mesenchymal Stem Cells (hWJ-MSCs)
Following cesarean section, umbilical cords from healthy
term deliveries (mean gestational age 38.9 (0.6) wk [standard
deviation]; n ¼ 5) were collected after informed consent. The
institutional review board of the University Hospital Bern and
the Canton of Bern approved the study. hWJ-MSCs were
isolated as described previously32 and cultured in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 supplemented with
10% fetal calf serum (FCS), 2 mmol/L glutamax, and 100
units/mL penicillin/100 mg/mL streptomycin (expansion
medium; Thermo Fisher Scientific, Waltham, MA, USA).
Isolation of hWJ-MSC-derived EVs
hWJ-MSC-derived EVs were isolated by serial centrifuga-
tions as described by The´ry et al.33 In brief, as hWJ-MSCs
reached 70% to 80% confluency, the cells were washed
twice with phosphate-buffered saline (PBS). The expansion
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medium was replaced by serum-free DMEM/F12 containing
2 mmol/L glutamax and 100 units/mL penicillin/100 mg/mL
streptomycin to avoid the contamination with EVs originating
from FCS. The conditioned medium (CM) for EV purifica-
tion was collected after 24 h of culture. The viability of
hWJ-MSCs was assessed by trypan blue exclusion using the
Countess II FL Automated Cell Counter (Thermo Fisher Sci-
entific). To pellet the cells, CMwas centrifuged at 300g for 10
min. The supernatant was centrifuged at 2,000g for 10 min to
remove dead cells. To pellet cellular debris, the supernatant
was centrifuged at 10,000g for 30 min. To finally obtain EVs,
the supernatant was centrifuged at 100,000g for 70 min. EVs
were washed with 5 mL PBS and centrifuged a second time at
100,000g for 70 min. The pelleted EVs were resuspended in
PBS and stored at 20 C until use.
Quantification and Characterization of hWJ-MSC-
derived EVs
The protein content of hWJ-MSC-derived EVs was
measured using the NanoVue Plus™ spectrophotometer
(Biochrom, Holliston, MA, USA). The isolated vesicles
were examined for the expression of endosomal proteins
by the Exo-Check-antibody array (System Biosciences, Palo
Alto, CA, USA) and by determining their size by negative-
staining electron microscopy.
Exo-Check antibody array. The semiquantitative Exo-Check
antibody array is a membrane-based assay with 12 pre-
printed spots comprising antibodies against the known
exosomal markers CD63, CD81, apoptosis-linked gene
2-interacting protein X (ALIX), flotillin 1, intercellular adhe-
sion molecule 1 (ICAM-1), epithelial cell adhesion molecule
(EpCAM), annexin A5 (ANXA5), and tumor susceptibility
gene 101 (TSG101). The GM130 cis-Golgi protein marker
acts as negative control to rule out cellular contamination.
The positive control contains human serum exosome pro-
teins. The Exo-Check antibody array was performed
according to the manufacturer’s protocol. Detection was
done by chemiluminescence using Amersham ECL Prime
Western blotting reagent (GE Healthcare Life Sciences,
Piscataway, NJ, USA) on a Chemidoc XRSþ system from
Bio-Rad Laboratories, Inc. (Hercules, CA, USA).
Negative-staining electron microscopy. For the imaging of nega-
tively stained samples, aliquots of 5 mL hWJ-MSC-derived
EVs were adsorbed on Formvar1 (Formvar resin 15/95, Ted
Pella, Inc., Redding, CA, USA) coated copper grids, washed
3 times with pure water, and stained with 2% uranyl acetate
solution (Electron Microscopy Sciences, Hatfield, PA, USA)
for 30 s. Excess fluid was removed by gently pushing them
sideways to filter paper. Samples were examined with a
transmission electron microscope (CM12, Philips, Eindho-
ven, the Netherlands), equipped with a digital camera (Mor-
ada, Soft Imaging System, Mu¨nster, Germany) and image
analysis software (iTEM; OSIS, Olympus Soft Imaging
Solutions, Mu¨nster, Germany). The mean EV diameter was
calculated using the ImageJ software (NIH, Bethesda, MD,
USA). To get pixels per nanometer, the length in pixels of
the scale bar was calculated with the tool “straight.” The
scale bar and truncated EVs at the border of the image were
cleared to exclude them from the analysis. Then, the image
was inverted and the threshold was adjusted using “auto-
threshold.” The EVs were analyzed for the parameters
“area” and “perimeter” using the following filter mask set-
tings: size (pixels^2) ¼ 1,000–1,5000; circularity ¼ 0.11–
1.00. The obtained pixels were converted to nanometer, and
the average diameter of the EVs was calculated from the area
and perimeter.
GRP94 Western Blotting of EVs
Twenty microliters of WJ-MSCs, lysed using the mammalian
cell lysis kit from Sigma-Aldrich (St. Louis, MO, USA), and
EVwere separated by sodiumdodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) on a 4% to 20% gradient gel
(Bio-Rad) to analyze the expression of the chaperone GRP94.
Separated proteins were transferred onto nitrocellulose mem-
branes (Thermo Fisher Scientific), blocked with 5%milk, and
analyzed with a rabbit antibody against GRP94 (1:500; Cell
Signalling Technology, Danvers, MA, USA). As secondary
antibody, horseradish peroxidase (HRP)-coupled donkey
anti-rabbit (1:1,000; GE Healthcare Life Sciences) was used.
Bindingwas detected by chemiluminescence usingAmersham
ECL Prime Western blotting reagent (GE Healthcare Life
Sciences) on a Chemidoc XRSþ system Bio-Rad.
Culture of Mouse Neuroblastoma Cell Line
Neuro2a (N2a)
The mouse neuroblastoma cell line N2a was purchased from
American Type Culture Collection (ATCC, Manassas, VA,
USA) and expanded in DMEM containing 10% FCS, 2
mmol/L glutamax, and 100 units/mL penicillin/100 mg/mL
streptomycin (N2a expansion medium). Trypsin-
ethylenediaminetetraacetic acid (EDTA, 0.25%; Thermo
Fisher Scientific) was used to detach N2a cells from
culture plates.
Oxygen–Glucose Deprivation and Reoxygenation
(OGD/R)
N2a cells were seeded at 9,000 cells/cm2 and cultured over-
night in N2a expansion medium. The next day, the N2a
expansion medium was replaced by glucose-free DMEM,
supplemented with 10% FCS, 2 mmol/L glutamax, and
100 units/mL penicillin/100 mg/mL streptomycin, and incu-
bated for 6 h at 37 C in 1% O2/5% CO2 (hypoxia). After
OGD, medium was replaced by N2a expansion medium and
returned into a normoxic incubator for 24 h or 48 h and
subsequently analyzed for cellular damage.
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To assess the protective and therapeutic effects of hWJ-
MSC-derived EVs, 0.1 mg/mL (2.02 pg/cell) or 1 mg/mL EVs
(20.2 pg/cell) were added either 24 h or 1 h before OGD
induction or directly after the 6 h of OGD. N2a cells were
analyzed after 24 h and 48 h of reoxygenation.
Terminal Deoxynucleotidyl Transferase deoxyuridine
triphosphate Nick End Labeling (TUNEL) Test
The In Situ Cell Death Detection Kit (Sigma-Aldrich) was
used to detect and quantify apoptosis based on the labeling
of DNA strand breaks. The cells were fixed with 4%
paraformaldehyde (PFA) in PBS, pH 7.4 for 1 h at room
temperature. Fixed cells were washed with PBS and per-
meabilized with 0.1% Triton X-100 in 0.1% sodium citrate
for 2 min on ice. Cells were washed twice with PBS and
stained with the TUNEL reaction mixture in a humified
atmosphere at 37 C for 1 h according to the manufacturer’s
protocol. Nuclei were counterstained with 40-6-diamidino-
2-phenylindole-dihydrochloride (DAPI, Sigma-Aldrich).
Stained cells were washed 3 times with PBS and analyzed
with a DM IL microscope (Leica Microsystems, Wetzlar,
Germany).
RNA Extraction from N2a cells, Reverse Transcription,
and Real-time Polymerase Chain Reaction (PCR)
RNA was extracted using the QIAshredder and the Allprep
DNA/RNA/Protein Mini Kits (Qiagen, Hilden, Germany),
according to the manufacturer’s protocol. The concentration
of RNA was assessed by a NanoVue Plus™ spectrophot-
ometer (Biochrom).
Up to 5 mg of total RNA were reverse transcribed by the
SuperScript III First-Strand Synthesis System (Thermo
Fisher Scientific). The transcription of caspase 3 (Casp3,
GE assay ID: Mm01195085_m1; Thermo Fisher Scientific)
and B-Cell CLL/lymphoma 2-associated agonist of cell
death (Bad, GE assay ID: Rn00575519_m1; Thermo Fisher
Scientific) was assessed by real-time PCR. The following
PCR cycling program was run on a 7300 Real-Time PCR
System (Thermo Fisher Scientific): 2 min at 50 C, 10 min at
95 C, followed by 45 cycles of 15 s at 95 C and 1 min at
60 C. The transcripts were normalized to the reference gene
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and
analyzed using the 7300 System Software (Thermo Fisher
Scientific). Data were expressed as fold change relative to
untreated N2a cells.
For the reverse transcription of miR, the miScript II RT
kit (Qiagen) was used. According to the manufacturer’s pro-
tocol, 125 to 250 ng of total RNA were needed per reaction.
The expression levels of let-7a (cat.no. MS00006482,
Qiagen) and let-7e (cat. no. MS00031227, Qiagen) were
measured by SYBRGreen-based real-time PCR. The follow-
ing PCR cycling program was used: 15 min at 95 C, fol-
lowed by 45 cycles of 15 s at 94 C, 30 s at 55 C, and 34 s at
70 C. Let-7a and let-7e levels were normalized to snord95
(cat. no. MS00033726, Qiagen) and analyzed using the 7300
System Software. Data were expressed as fold change rela-
tive to untreated N2a cells.
RNA Extraction from EV, Reverse Transcription,
and Real-time PCR of miR
EV RNA was extracted using the Total Exosome RNA and
Protein Isolation kit (Thermo Fisher Scientific). miR was
reverse transcribed using the miScript II RT kit (Qiagen).
The human Neurological Development and Disease
miScript™ miRNA PCR Array (Cat. No. MIHS-107Z;
Qiagen) is an SYBR Green-based real-time PCR array and
was used to profile the presence of mature miR involved in
neurological development and progression of neurological
diseases in EVs. For one 96-well plate, 100 mL of cDNA,
which was pooled equally from 4 different EV preparations,
were mixed with 1,375 mL of 2 QuantiTect SYBR Green
PCR Master Mix (Cat.No. 218073) and 275 mL of 10
miScript Universal Primer and filled up with RNase-free
water to the final volume of 2,750 mL. Twenty-five micro-
liters of the PCR component mix were pipetted into each
well of the PCR array. The PCR was run with the following
PCR cycling program on a 7300 Real-Time PCR System
(Thermo Fisher Scientific): 15 min at 95 C, followed by
45 cycles of 15 s at 94 C, 30 s at 55 C, and 34 s at 70 C.
The online database miRDB.org was used for miR target
gene prediction. Using a computational target prediction
algorithm, the program calculates the probability of the bind-
ing of the miR to a certain gene, which yields a target score
between 50 and 100. The higher the target score is, the more
likely is the binding.
Protein Isolation and p-BAD Serine at Position 112
(Ser112) Western Blotting
Protein was isolated using the QIAshredder and the Allprep
DNA/RNA/Protein Mini Kits (Qiagen) according to the
manufacturer’s protocol. Total protein concentration was
measured by the bicinchoninic acid protein assay kit
(Sigma-Aldrich).
Proteins were separated by SDS-PAGE on a 15% gel for
the analysis of the phosphorylation of BAD at the Ser112 site
(p-BADSer112). Separated proteins were transferred onto
nitrocellulose membranes (Thermo Fisher Scientific),
blocked with 5% bovine serum albumin (BSA) and analyzed
with a rabbit antibody against p-BADSer112 (1:500; Cell
Signalling Technology). HRP-coupled donkey anti-rabbit
(1:1,000; GE Healthcare Life Sciences) was used as second-
ary antibody. Binding was detected by chemiluminescence
using Amersham ECL Prime Western blotting reagent (GE
Healthcare Life Sciences) on a Chemidoc XRSþ system
from Bio-Rad Laboratories GmbH.
ImageJ software was used for pixel summation of individ-
ual bands. Pixel intensities were corrected for background.
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p-BADSer112 intensities were standardized to the corre-
sponding b-actin bands.
Culture of N2a Cells with Chloromethyl (CM)-Dil- and
Exo-Red-labeled hWJ-MSC-derived EVs
EVs were stained with 2 mM of the fluorescent celltracker™
dye CM-Dil (Thermo Fisher Scientific) according to the
manufacturer’s protocol. CM-Dil-stained EVs were centri-
fuged for 70 min at 100,000g at 4 C and resuspended in
PBS. 37,500 N2a cells/cm2 were cultured with 5 mg/mL CM-
Dil-stained EVs for 24 h. Nuclei were counterstained with
DAPI (Sigma-Aldrich). Optical sections were taken using a
Zeiss LSM 710 (Carl Zeiss AG, Feldbach, Switzerland),
with a 63 oil objective (Plan-Apochromat 63/1.40 Oil
DIC M27) and a digital zoom of 1.0.
EV RNA was labeled with the red fluorescent Exo-Red
(Exo Glow™ Exosome labeling kit, System Biosciences)
according to the manufacturer’s protocol. Exo-Red-stained
EVs were cultured for 2 h with 37,500 N2a cells/cm2. Nuclei
were counterstained with DAPI (Sigma-Aldrich). Analysis
was done on a DM6000 B microscope (Leica Microsystems).
Statistical Analysis
Statistical analysis was done using the SigmaPlot software
version 11.0 (Systat Software, Inc., Chicago, IL, USA). To
calculate the significance of real-time PCR data, one-way
repeated measures analysis of variance (ANOVA) was per-
formed, followed by the all pairwise multiple comparison
Holm-Sidak test in case of a significant effect. t-tests were
used for the statistical analysis of the TUNEL data. All
experimental groups were compared to the OGD/R group.
P < 0.05 was considered statistically significant.
Results
Characterization of hWJ-MSC-derived EVs
The viability of hWJ-MSCs after 24 h culture in serum-free
medium was 91.08 + 3.79%, as assessed by trypan blue
exclusion. Over this period of time, 6.14 mg + 3.48 EVs,
quantified by their protein content, were released by 106
hWJ-MSCs. To assess whether the isolated hWJ-MSC-
derived vesicles were of endosomal origin, they were ana-
lyzed for the expression of endosomal proteins, the absence
of GM130, a cis-Golgi protein marker, and GRP94, which is
the most abundant chaperone protein in the endoplasmic
reticulum lumen, and for their size by negative-staining elec-
tron microscopy (Fig. 1A to D). hWJ-MSC-derived vesicles
were positive for endosome-specific proteins, such as
TSG101, ANXA5, tetraspanin CD81, and ALIX (Fig. 1A).
Additionally, EVs were negative for GM130 and GRP94,
ruling out the presence of organelle fractions, such as Golgi
Fig. 1. Characterization of human Wharton’s jelly mesenchymal stem cells (hWJ-MSC)-derived extracellular vesicles (EVs). (A) Represen-
tative Exo-Check antibody array of isolated hWJ-MSC-derived EVs. The antibody array has been done with 4 different EV preparations.
(B) Western blot analysis of GRP94 expression in hWJ-MSC lysates and hWJ-MSC-derived EVs. Anti-b-actin staining was used as loading
control, even though it is more abundant in cells than in EVs. To prove absent GRP94 expression in EVs, the membrane was overexposed.
Western blot analysis has been done for 3 different EV preparations. (C) Representative electron microscopy image of hWJ-MSC-derived
EVs, (D) revealing a mean vesicle diameter of 34.34 nm. Electron microscopy has been performed with 2 different EV preparations.
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apparatus and endoplasmic reticulum, a hallmark of apopto-
tic bodies, in the isolated EVs (Fig. 1A and B).
Electron microscopy revealed that the EVs were similar
in size and had a roundish morphology (Fig. 1C). The mean
diameter of the EVs in Fig. 1C was determined (Fig. 1D).
The calculation of the length of the 200 nm scale bar yielded
812 pixels, assuming that 1 nm corresponds to 4.06 pixels.
The calculated diameters in pixels were converted into nan-
ometer, resulting in a mean EV diameter of 34.34 nm.
hWJ-MSC-derived EVs Prevent OGD/R-triggered
Apoptosis in N2a Cells
To evaluate the neuroprotective potential of EVs generated
from hWJ-MSCs on neural cells after an HI insult, we estab-
lished an OGD/R in vitro model. As the mouse neuroblas-
toma cell line N2a has been previously used to study
neuroprotection in vitro34, we subjected N2a cells to 6 h of
OGD, followed by 24 h and 48 h of reoxygenation, respec-
tively. hWJ-MSC-derived EVs were added 24 h or 1 h before
the onset of OGD (Fig. 2A).
Six hours of OGD and 24 h of reoxygenation significantly
increased the percentage of TUNEL-positive cells relative to
the undamaged N2a cells (P ¼ 0.0057; Fig. 2E). The addi-
tion of 0.1 mg/mL (ca. 2 pg/cell; P ¼ 0.003) or 1 mg/mL
(ca. 20 pg/cell; P ¼ 0.004) EVs to N2a cells 1 h before the
initiation of OGD prevented the increase of OGD/R-
mediated TUNEL expression (Fig. 2E).
Given that Casp3 activation plays a key role in the HI
damage of immature brain35–37, we assessed Casp3 expres-
sion in N2a cells subjected to OGD/R. In response to 6 h of
OGD and 48 h of reoxygenation, Casp3 levels were signif-
icantly upregulated (P¼ 0.002), which was prevented by the
addition of 0.1 mg/mL (ca. 2 pg/cell; P¼ 0.024) and 1 mg/mL
(ca. 20 pg/cell; P ¼ 0.048) EV 24 h and 0.1 mg/mL
(ca. 2 pg/cell; P ¼ 0.024) EV 1 h before OGD exposure
(Fig. 2F). Six hours of OGD followed by 24 h of reoxygena-
tion did not alter Casp3 transcription in N2a cells compared
to control cells (data not shown).
A further key player during apoptosis is the proapoptotic
Bcl-2 family member BAD38. The transcription of Bad was
significantly increased in N2a cells relative to undamaged
N2a cells in response to 6 h of OGD and 48 h of reoxygena-
tion (P ¼ 0.024; Fig. 2G). The addition of 0.1 mg/mL
(ca. 2 pg/cell) and 1 mg/mL (ca. 20 pg/cell) EV 24 h and
1 h before OGD/R, however, did not significantly increase
Bad (Fig. 2G). At the protein level, the proapoptotic activity
of BAD is regulated by phosphorylation. Phosphorylated
BAD (p-BAD) is restrained in the cytosol. The dephosphor-
ylation of BAD results in the translocation to mitochondria
promoting the release of cytochrome C. BAD contains 3
phosphorylation sites. Here, we studied the phosphorylation
of Ser112 (p-BADSer112) by Western blotting. Six hours of
OGD and the reoxygenation of 24 h and 48 h, respectively,
did not alter the expression of p-BADSer112 (Figs. 2H and
3G). In contrast, the addition of 0.1 mg/mL and 1 mg/mL EVs
24 h and 1 h before OGD, followed by 24 h or 48 h of
reoxygenation, respectively, enhanced the level of p-
BADSer112 by trend (Fig. 2H).
hWJ-MSC-derived EVs Resolve OGD/R-triggered
Apoptosis in N2a Cells
From a clinical point of view, the neuroregenerative effects
of EVs are more relevant than the neuroprotective ones.
Thus, we investigated the potential curative effects of
hWJ-MSC-derived EVs on OGD/R subjected N2a cells.
EVs were added immediately after OGD (Fig. 3A). The
treatment of N2a cells with 1 mg/mL (ca. 20 pg/cell)
hWJ-MSC-derived EVs after OGD and 24 h of reoxygena-
tion resolved the rise of TUNEL-positive cells caused by
OGD/R (P ¼ 0.02; Fig. 3E).
Furthermore, the treatment with both 0.1 mg/mL
(ca. 2 pg/cell; P ¼ 0.024) or 1 mg/mL (ca. 20 pg/cell;
P¼ 0.024) hWJ-MSC-derived EVs reversed the upregulated
transcription of Casp3 in N2a cells after 48 h of reoxygena-
tion (Fig. 3F). However, 24 h of reoxygenation did not alter
Casp3 in N2a cells relative to control cells (data not shown).
Bad expression was not affected by the treatment with EVs
after 6 h OGD and 24 h or 48 h of reoxygenation, respec-
tively (data not shown).
Furthermore, the treatment of N2a cells after OGD with
0.1 mg/mL (ca. 2 pg/cell) or 1 mg/mL (ca. 20 pg/cell) EVs,
followed by 24 h or 48 h of reoxygenation, respectively,
tended toward an increased phosphorylation of BAD
(p-BADSer112; Fig. 3G).
hWJ-MSC-derived EVs Get Internalized by N2a Cells
As hWJ-MSC-derived EVs had neuroprotective and neuror-
egenerative effects on N2a cells, we next assessed how hWJ-
MSC-derived EVs interacted with N2a cells. For this reason,
the EVs were stained with the red fluorescent lipophilic dye
CM-Dil prior to the coculture with N2a cells. Fluorescence
confocal microscopy revealed colocalization of the EVs and
the cells after 24 h of coculture (Fig. 4A and B). hWJ-MSC-
derived EVs mostly formed aggregates and were localized
close to the nuclei of N2a cells.
hWJ-MSC-derived EVs Contain miR Targeting
Proapoptotic Genes and Release Their RNA Content
into N2a Cells
Along with DNA, mRNA, proteins, and lipids, EV transport
highly conserved, small noncoding miR molecules, which
have decisive functions in gene regulation29. Thus, addres-
sing the potential molecular mechanism of neuroprotection
and neuroregeneration, we next evaluated whether hWJ-
MSC-derived EVs transfer their RNA into N2a cells. EV
RNA was stained with the red fluorescent dye Exo-Red prior
to the coculture with N2a cells. After 2 h of co-incubation,
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Fig. 2. Prevention of oxygen–glucose deprivation/reoxygenation (OGD/R)-triggered apoptosis in neuro2a (N2a) cells by humanWharton’s
jelly mesenchymal stem cells (hWJ-MSC)-derived extracellular vesicles (EVs). N2a cells were either left undamaged or subjected to 6 h of
oxygen–glucose deprivation (OGD), followed by 24 h or 48 h of reoxygenation, respectively. To test the neuroprotective capacity of hWJ-
MSC-derived EVs, 0.1 mg/mL (ca. 2 pg/cell) or 1 mg/mL EVs (ca. 20 pg/cell) were added to the cells 24 h or 1 h before OGD induction.
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Fig. 2. (continued) (A) Experimental outline. (B to H) After the pretreatment with EVs 1 h before OGD and 24 h of reoxygenation, N2a
cells were evaluated by terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling (TUNEL) test. TUNEL-positive
cells are marked by arrows. N2a nuclei were counterstained with 40,6-diamidino-2-phenylindole (DAPI). Representative images of unda-
maged N2a cells (B), N2a cells subjected to OGD/R (C), and N2a cells pretreated with 1 mg/mL EVs before OGD initiation (D).
(E) Differences in TUNEL-positive cells relative to DAPI. Bars illustrate mean + standard error of mean (SEM) of 6 different images.
*P < 0.05, **P < 0.01. Student’s t-test. (F and G) Real-time polymerase chain reaction analysis of caspase 3 and B cell lymphoma 2-associated
antagonist of cell death (Bad) transcription post 48 h of reoxygenation. Bars illustrate mean+ SEM of 3 independent experiments. *P < 0.05,
**P < 0.01. Analysis of variance with post hoc Holm-Sidak test. (H) Western blot analysis for phosphorylation of BAD at the serine at
position 112 site expression.
Fig. 3. Reversion of oxygen–glucose deprivation/reoxygenation (OGD/R)-triggered apoptosis in neuro2a (N2a) cells by human Wharton’s
jelly mesenchymal stem cells (hWJ-MSC)-derived extracellular vesicles (EVs). N2a cells were either left undamaged or subjected to 6 h of
oxygen–glucose deprivation (OGD), followed by 24 h or 48 h of reoxygenation, respectively. To test for the neuroregenerative capacity of
hWJ-MSC-derived EVs, 0.1 mg/mL (ca. 2 pg/cell) or 1 mg/mL EVs (ca. 20 pg/cell) were added after 6 h of OGD. (A) Experimental outline. (B to
G) After the treatment with EV post-OGD, followed by 24 h of reoxygenation, N2a cells were evaluated by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) test. TUNEL-positive cells are marked by arrows. N2a nuclei were counterstained with 40,6-
diamidino-2-phenylindole (DAPI). Representative images of undamaged N2a cells (B), N2a cells subjected to OGD/R (C), and N2a cells
treated with 1 mg/ml EVs after OGD (D). (E) Differences in TUNEL-positive cells relative to DAPI. Bars illustrate mean+ standard error of
mean (SEM) of 6 different images. *P < 0.05, **P < 0.01. Student’s t-test. (F) Real-time polymerase chain reaction (PCR) analysis of caspase 3
transcription post 48 h of reoxygenation. Bars illustrate mean + SEM of 3 independent experiments. *P < 0.05, **P < 0.01. Analysis of
variance with post hoc Holm-Sidak test. (G) Western blot analysis for phosphorylation of BAD at the serine at position 112 site expression.
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N2a cells were highly positive for Exo-Red, confirming the
delivery of EV RNA into N2a cells (Fig 4C).
Knowing that hWJ-MSC-derived EVs release their RNA
into N2a cells, we were characterizing the miR content of
hWJ-MSC-derived EVs by real-time PCR. Potentially rele-
vant mature miRs targeting proapoptotic genes, being pres-
ent in the isolated hWJ-MSC-EVs and their predicted target
genes with a target gene 70 (according to miRDB.org), are
listed in Table 1. EVs contained mature miR, which are very
likely to target and regulate the expression of numerous
proapoptotic genes, including BCL2 family members, BCL2
interacting molecules, BCL10 and Harakiri (HRK), and cas-
pases, in particular Casp3.
As shown above, hWJ-MSC-derived EVs prevented
(Fig. 2E) and reversed (Fig. 3E) the OGD/R-mediated upre-
gulation of Casp3. Casp3 levels are largely regulated by the
let-7-5p miR family39,40, and hWJ-MSC-derived EVs con-
tained members of the let-7-5p family, as measured by real-
Fig. 4. Human Wharton’s jelly mesenchymal stem cells (hWJ-MSC)-derived extracellular vesicles (EVs) interact with and deliver their RNA
into neuro2a (N2a) cells. hWJ-MSC-derived EVs were either labeled with the membrane dye chloromethyl (CM)-Dil (red) or the RNA dye
Exo-Red and cocultured with N2a cells. The nuclei of N2a cells were counterstained with 4-6-diamidino-2-phenylindole-dihydrochloride
(DAPI) (blue). (A) Representative fluorescent confocal microscopy image after the coculture of CM-Dil-stained EV and N2a cells for 24 h.
(B) Three-dimensional visualization of the coculture of CM-Dil-stained EV and N2a cells by fluorescent confocal microscopy. (C) Repre-
sentative fluorescent microscopy image after 2 h of coculture of Exo-Red-stained EV RNA and N2a cells. (D) Real-time polymerase chain
reaction (PCR) analysis of let-7a and let-7e expression in N2a cells after 6 h oxygen-glucose deprivation (OGD) and 24 h of reoxygenation
with and without the pretreatment with 1 mg/mL EVs (ca. 20 pg/cell) 24 h or 1 h before OGD initiation, relative to undamaged N2a cells. (E)
Real-time PCR analysis of let-7a and let-7e expression in N2a cells after 6 h OGD and 24 h of reoxygenation with and without the treatment
with 1 mg/mL EVs after 6 h of OGD, relative to undamaged N2a cells. Bars illustrate mean+ standard error of mean (SEM) of 3 independent
experiments; *P < 0.05, **P < 0.01. Analysis of variance with post hoc Holm-Sidak test.
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time PCR (Table 1). Thus, we next measured the levels of
let-7a and let-7e in N2a cells after OGD/R with and without
EVs. Six hours of OGD and 24 h of reoxygenation
significantly decreased let-7a (P ¼ 0.032) and let-7e (P ¼
0.003) expression in N2a cells relative to undamaged cells
(Fig. 4D). Adding 1 mg/mL (ca. 20 pg/cell) EVs 1 h before
OGD/R significantly increased let-7e expression in N2a cells
compared to damaged cells (P ¼ 0.010). However, let-7e
levels did not change when 1 mg/mL EVs were added 24 h
before OGD/R induction relative to damaged cells. Let-7a
expression was not significantly altered in N2a cells when 1
mg/mL EVs were added 24 h or 1 h before the onset of OGD/
R (Fig. 4D). No changes in let-7a and let-7e levels were
detected after 48 h of reoxygenation (data not shown).
The significant decrease of let-7a in N2a cells subjected
to 6 h OGD and 24 h reoxygenation was reversed by the
addition of 1 mg/mL EVs directly after OGD (ca. 20 pg/cell;
P ¼ 0.021; Fig. 4E). Although 6 h OGD and 24 h of
reoxygenation significantly declined let-7e levels in N2a
cells (P ¼ 0.003), treatment with EVs post-OGD did not
increase let-7e expression levels to a significant degree
(Fig. 4E). No alterations of let-7a and let-7e expression were
measured after 48 h of reoxygenation (data not shown).
Discussion
We successfully isolated EVs derived from hWJ-MSCs by
serial high-speed centrifugation and ultracentrifugation.
Obtained EV preparations were derived from endosomes and
were not contaminated by organelle-bearing apoptotic bod-
ies, verified by the absent expression of the Golgi complex
marker CM130 and the endoplasmic chaperone GRP94,
their nanoscale size, and their morphology.
We showed that OGD/R-initiated apoptosis could be
prevented and resolved by hWJ-MSC-derived EVs. The
treatment of N2a cells with hWJ-MSC-derived EVs even
post-OGD initiation rectified the apoptotic cascade.
We observed that hWJ-MSC-derived EVs interfere with
the apoptotic cascade at the transcriptional level of Casp3
and at the phosphorylation status of the pro-apoptotic Bcl2
protein family member BAD. By forming a pore in the mito-
chondrial outer membrane, the Bcl2 family regulates a key
step in the initiation of the apoptotic pathway41. The
proapoptotic activity of BAD is regulated by the phosphor-
ylation of serines. In normal cells, BAD is phosphorylated
and therefore inactive and sequestered into the cytoplasm.
Non-p-BAD is active by forming heterodimers with the anti-
apoptotic BCL-2 members BCL-2 and BCL-XL and, thus,
initiating the apoptotic cascade. While the transcription of
Bad was increased in N2a cells after OGD/R, the addition of
hWJ-MSC-derived EVs before and after the OGD exposure
of N2a cells, respectively, did not significantly prevent or
resolve the elevated Bad gene expression, indicating that
hWJ-MSC-derived EVs do not regulate the transcription of
Bad. However, a higher sample number would be needed to
test for significance. At the protein level, phosphorylation of
BAD in N2a cells did not change after OGD/R, suggesting
that OGD/R-mediated apoptosis in N2a cells is rather trig-
gered by the increased transcription of Bad—and probably
by translation into unphosphorylated BAD—than by the
desphosphorylation of p-BAD. hWJ-MSC-derived EVs,
added before or after OGD initiation, tended to increase the
phosphorylation of BAD in N2a cells, providing evidence
that hWJ-MSC-derived EVs interfere with apoptosis, at least
in part, by increasing the proportion of the inactive p-BAD
relative to the proapoptotic unphosphorylated BAD. How-
ever, to complete this hypothesis, the p-BADSer112/BAD
ratio should be determined.
The sequential activation of caspases, a cysteine protease
family, is pivotal in the execution stage of apoptosis and is
required for neurodegeneration in neonatal HI brain dam-
age4–6. In living cells, caspases are present as inactive
Table 1. Mature miR Content of hWJ-MSC-derived EVs and Their
Proapoptotic Target Genes with Target Scores 70 (miRDB.org) .
Mature miR Target Gene
let-7b-5p Casp3
let-7c-5p Casp3
let-7d-5p Casp3
let-7e-5p Casp3
let-7i-5p Casp3
miR-9-3p BNIP3L
miR-20a-5p Casp8
miR-24-3p BOK; BNIP3L; BCL2L11
miR-26b-5p CRADD
miR-28-5p Casp2
miR-29a-3p HRK; BMF
miR-29b-3p HRK; BMF
miR-29c-3p HRK; BMF
miR-30d-5p BNIP3L; BCL10
miR-34a-5p Casp2; BCL2L13
miR-92a-3p BCL2L11
miR-93-5p Casp8
miR-98-5p Casp3
miR-106b-5p Casp8
miR-125-5p BCL2L14; BMF
miR-133b BNIP3L
miR-138-5p Casp7; BNIP3L
miR-181a-5p BCLAF1
miR-181d-5p BCLAF1
miR-203a-3p BCL2L11
miR-298 BCL2L1
miR-320a BNIP3
miR-342-3p Casp2
miR-409-3p BNIP3L
miR-432-5p Casp14
Abbreviations: EVs, extracellular vesicles; hWJ-MSCs, human Wharton’s jelly
mesenchymal stem cells; miR, microRNA; Casp3, caspase 3; BNIP3L, BCL2
interacting protein 3 like; Casp8, caspase 8; BOK, BOK, BCL2 family apoptosis
regulator; BCL2L11, BCL2 like 11; CRADD,CASP2 and RIPK1 domain contain-
ing adaptor with death domain; Casp2, caspase 2; HRK, harakiri, BCL2 interact-
ing protein; BMF, Bcl2 modifying factor; BCL10, B-cell CLL/lymphoma 10;
BCL2L13, BCL2 like 13; Casp8, caspase 8; Casp3, caspase 3; BCL2L14, BCL2
like 14; Casp7; caspase 7; BCLAF1, BCL2 associated transcription factor 1;
BCL2L1, BCL2 like 1; BNIP3, BCL2 interacting protein 3; Casp14, caspase 14.
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proenzymes. After the initiation of the apoptotic cascade,
caspases are cleaved into 2 subunits, which for their part
dimerize and build up the active enzyme42. The addition of
hWJ-MSC-derived EVs to N2a cells both prior to and post-
OGD exposure prevented and resolved the OGD/R-triggered
transcription of Casp3, emphasizing their neuroprotective
and neuroregenerative capacity. As the let-7-5p miR family
is known to regulate Casp339,40 and we observed that hWJ-
MSC-derived EVs contained several members of the let-7-
5p miR family, along with numerous other miR targeting
proapoptotic genes, we hypothesized that EV-derived let-
7-5p miR regulated Casp3 expression in N2a cells. Indeed,
we showed that hWJ-MSC-derived EVs transferred their
RNA into N2a cells. Furthermore, the expressions of Casp3,
and let-7a and let-7e, respectively, were reciprocal, provid-
ing evidence that hWJ-MSC-derived EVs disturbed the
OGD/R-mediated increase of Casp3 by their let-7-5p miR
cargo. However, the significant differences in let-7a and let-
7e were measured after 24 h of reoxygenation, whereas
changes in Casp3 were significant only after 48 h of reox-
ygenation, indicating that the let-7-5p miR family negatively
regulates Casp3 expression by progressive mRNA degrada-
tion. The transfer of functional miR from MSC exosomes
into target cells has also been demonstrated lately in several
animal models, such as optic nerve crush, myocardial infarc-
tion, and right MCAO22,43,44.
In conclusion, our present study suggests that hWJ-
MSC-derived EVs protect against HI-induced neuronal cell
death, which is of interest in regard to a previous report
documenting a protective effect of EVs derived from
human umbilical cord tissue–derived MSCs against
H2O2-triggered cell death in rat myoblasts and kidney cells
and human liver cells45. Not only the neuroprotective
capacity, but especially the neuroregenerative potential in
HI-mediated damage by hWJ-MSC-derived EVs bears
good prospects for their future clinical application in peri-
natal brain injury. However, before considering clinical
practice, further investigation will be required on the mole-
cular mechanisms of neuroprotection and neuroregenera-
tion mediated by hWJ-MSC-derived EVs. To complete
our understanding of hWJ-MSC-derived EVs as a therapeu-
tic agent, the neuroprotective and neuroregenerative poten-
tial of hWJ-MSC-derived EVs has to be confirmed in a
preclinical animal model of perinatal HI brain damage.
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